APG 1252

Drug Profile

APG 1252

Alternative Names: APG-1252

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics
  • Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Dec 2017 Phase-I clinical trials in Small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT03387332)
  • 28 Dec 2017 Phase-I clinical trials in Solid tumours (First-line therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT03387332)
  • 26 Jun 2017 China Food and Drug Administration (CFDA) approves IND for APG 1252 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top